{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T14:22:18Z","timestamp":1758637338400,"version":"3.44.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1053\/j.seminhematol.2023.12.002","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T05:53:01Z","timestamp":1702360381000},"page":"322-328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effective sequencing of chimeric antigen receptor T-cell therapy in the treatment of LBCL in 2023"],"prefix":"10.1053","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2588-1943","authenticated-orcid":false,"given":"Christine E.","family":"Ryan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caron A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1053\/j.seminhematol.2023.12.002_bib0001","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"181","key":"10.1053\/j.seminhematol.2023.12.002_bib0002","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-3-540-73259-4_14","article-title":"The T-body approach: redirecting T cells with antibody specificity","author":"Eshhar","year":"2008","journal-title":"Handb Exp Pharmacol"},{"issue":"4","key":"10.1053\/j.seminhematol.2023.12.002_bib0003","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1200\/JCO.18.01457","article-title":"CD19 chimeric antigen receptor therapy for refractory aggressive B-Cell lymphoma","volume":"37","author":"Jacobson","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.12.002_bib0004","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"issue":"26","key":"10.1053\/j.seminhematol.2023.12.002_bib0005","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.12.002_bib0006","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1053\/j.seminhematol.2023.12.002_bib0007","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"27","key":"10.1053\/j.seminhematol.2023.12.002_bib0008","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"27","key":"10.1053\/j.seminhematol.2023.12.002_bib0009","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10254","key":"10.1053\/j.seminhematol.2023.12.002_bib0010","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2023.12.002_bib0011","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1182\/blood-2021-148948","article-title":"Two-year follow-up of transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R\/R) large B-cell lymphomas (LBCL)","volume":"138","author":"Abramson","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.12.002_bib0012","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.12.002_bib0013","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.seminhematol.2023.12.002_bib0014","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1053\/j.seminhematol.2023.12.002_bib0015","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1053\/j.seminhematol.2023.12.002_bib0016","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2023.12.002_bib0017","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2021","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1053\/j.seminhematol.2023.12.002_bib0018","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"10.1053\/j.seminhematol.2023.12.002_bib0019","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2021","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1053\/j.seminhematol.2023.12.002_bib0020","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1182\/blood.2022015789","article-title":"CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?","volume":"139","author":"Westin","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.12.002_bib0021","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1053\/j.seminhematol.2023.12.002_bib0022","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2023.12.002_bib0023","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2022-158303","article-title":"Outcomes of subsequent anti-lymphoma therapies in patients (Pts) with large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (Axi-Cel) or standard of care (SOC) in the second-line (2L) ZUMA-7 study","volume":"140","author":"Ghobadi","year":"2022","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2023.12.002_bib0024","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2023.12.002_bib0025","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jtct.2022.07.011","article-title":"Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B cell lymphomas","volume":"28","author":"Riedell","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1053\/j.seminhematol.2023.12.002_bib0026","doi-asserted-by":"crossref","first-page":"581 e1- e8","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"21","key":"10.1053\/j.seminhematol.2023.12.002_bib0027","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1053\/j.seminhematol.2023.12.002_bib0028","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1053\/j.seminhematol.2023.12.002_bib0029","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2023.12.002_bib0030","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","volume":"108","author":"Kwon","year":"2023","journal-title":"Haematologica"},{"issue":"9","key":"10.1053\/j.seminhematol.2023.12.002_bib0031","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.bbmt.2020.06.008","article-title":"Comparing efficacy, safety, and preinfusion period of axicabtagene ciloleucel versus tisagenlecleucel in relapsed\/refractory large B cell lymphoma","volume":"26","author":"Oluwole","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1053\/j.seminhematol.2023.12.002_bib0032","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1016\/j.bbmt.2020.08.032","article-title":"Letter to the editor regarding \"comparing efficacy, safety, and preinfusion period of axicabtagene ciloleucel versus tisagenlecleucel in relapsed\/refractory large B cell lymphoma","volume":"26","author":"Zhang","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1053\/j.seminhematol.2023.12.002_bib0033","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2023.12.002_bib0034","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2022-160216","article-title":"Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (Liso-cel) versus axicabtagene ciloleucel (Axi-cel) for second-line (2L) treatment of patients (Pt) with refractory\/early relapsed (R\/R) large b-cell lymphoma (LBCL)","volume":"140","author":"Abramson","year":"2022","journal-title":"Blood"},{"issue":"26","key":"10.1053\/j.seminhematol.2023.12.002_bib0035","first-page":"3153","article-title":"Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction","volume":"141","author":"Selli","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2023.12.002_bib0036","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"},{"issue":"14","key":"10.1053\/j.seminhematol.2023.12.002_bib0037","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"International non-Hodgkin's Lymphoma Prognostic Factors P. A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"Shipp","year":"1993","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1053\/j.seminhematol.2023.12.002_bib0038","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Advances"},{"issue":"16_suppl","key":"10.1053\/j.seminhematol.2023.12.002_bib0039","article-title":"ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma","volume":"41","author":"Jacobson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2023.12.002_bib0040","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.12.002_bib0041","article-title":"Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy","author":"Iacoboni","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2023.12.002_bib0042","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US lymphoma CAR T consortium","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2023.12.002_bib0043","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2023.12.002_bib0044","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/14712598.2021.1884677","article-title":"Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma","volume":"21","author":"Salles","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1053\/j.seminhematol.2023.12.002_bib0045","article-title":"CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS","author":"Sakemura","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2023.12.002_bib0046","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2023.12.002_bib0047","first-page":"303","article-title":"The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma","volume":"140","author":"Calabretta","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2023.12.002_bib0048","doi-asserted-by":"crossref","first-page":"e48751b3","DOI":"10.1097\/01.HS9.0000971500.48751.b3","article-title":"Bendamustine-containing regimens can be safely used as bridging in large b-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy","volume":"7","author":"Garcia-Calvo","year":"2023","journal-title":"HemaSphere"},{"issue":"12","key":"10.1053\/j.seminhematol.2023.12.002_bib0049","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2023.12.002_bib0050","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1182\/blood-2022-158278","article-title":"Subcutaneous Epcoritamab\u202f+\u202fR-Dhax\/C in patients with relapsed or refractory diffuse large B-cell lymphoma eligible for autologous stem cell transplant: updated phase 1\/2 results","volume":"140","author":"Abrisqueta","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2023.12.002_bib0051","doi-asserted-by":"crossref","first-page":"e004475","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"14","key":"10.1053\/j.seminhematol.2023.12.002_bib0052","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1182\/bloodadvances.2022009309","article-title":"A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma","volume":"7","author":"Shouse","year":"2023","journal-title":"Blood Adv"},{"issue":"19","key":"10.1053\/j.seminhematol.2023.12.002_bib0053","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"10.1053\/j.seminhematol.2023.12.002_bib0054","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196323000951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196323000951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:28:44Z","timestamp":1758522524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196323000951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0037196323000951"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2023.12.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"type":"print","value":"0037-1963"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effective sequencing of chimeric antigen receptor T-cell therapy in the treatment of LBCL in 2023","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2023.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}